Lymphedema is one of the most common long-term consequences of breast cancer treatment. Damage to the lymphatic system during axillary surgery or radiation disrupts the drainage network that keeps fluid moving through the arm and chest wall. The result: chronic swelling, heaviness, restricted movement, recurring infections, and a daily management routine that defines life after treatment for many people.
For years, the management toolkit was compression garments, manual lymphatic drainage, and physical therapy. Evidence-based, genuinely helpful, and for many patients the only option they were ever offered.
The Procedures Exist
Microsurgical treatment of lymphedema has advanced substantially over the past decade. Lymphaticovenous anastomosis (LVA) connects lymphatic channels directly to small veins, restoring drainage where the system has failed. Vascularized lymph node transfer (VLNT) relocates functioning lymph node tissue from a donor site (e.g. inguinal, supraclavicular, or submental lymph node basins) to rebuild what was removed or damaged. Vascularized omentum lymph node transfer (VOLT) uses omental tissue and offers another approach for complex cases. Performed in well-selected candidates, these procedures can dramatically reduce dependence on compression and significantly improve quality of life. When performed prophylactically at the time of mastectomy or reconstruction, they can reduce the likelihood of lymphedema developing at all.
The surgery works. The problem is the system that can’t scale access to it.
Only a handful of centers in the United States have the microsurgical subspecialty depth to perform this work reliably. That concentration isn’t a clinical failure. Expertise at this level takes years to build and requires sustained case volume to maintain. The failure is what happens downstream: people who were never told these options exist, who spent years managing a chronic condition with the only tools that were offered, and who would have been candidates for a better outcome if the system around them had been designed to reach them.
That’s not a gap in what medicine can do. It’s a gap in what the system delivers.
Building the National Infrastructure
At PRMA in San Antonio, where I serve as CEO, Dr. Anton Fries leads the lymphedema program we built from the ground up. It draws patients nationally. Building that referral network has been a deliberate, ongoing effort for us, and the clinical results have validated the model: the right surgeon, the right pathway, and a system designed to reach people whose care teams hadn’t raised surgery as a possibility.
The harder problem is scale. A program that works in one city doesn’t automatically help a patient in Georgia or California or Alaska or Hawaii. That requires infrastructure most practices have never built.
Dr. Joe Dayan, formerly of Memorial Sloan Kettering, leads the lymphedema surgery program at The Plastic Surgery Center (TPSC) in New Jersey and brings a level of subspecialty depth in this work that few centers can match. Critically, he also developed the central intake process that makes a national approach to lymphedema surgery operationally possible. A patient anywhere in the country shouldn’t have to know which center to call. The intake process handles that routing, aligns the clinical evaluation, and ensures the right patient reaches the right surgeon regardless of where they start.
He and Dr. Fries now work together to align clinical standards across both centers. That physician-to-physician collaboration is the foundation for what’s coming next through ARSA: expanding this subspecialty capability across additional states, in more markets, with the same clinical infrastructure underneath it.
It’s complex to build. It requires the right people and the operational scaffolding to make referrals flow reliably. It compounds, though. Each center that comes online extends the network’s reach, and every patient who reaches care they couldn’t access before is evidence that the model is working.
Access Is a Clinical Outcome
The patient living with a swollen arm two years after their mastectomy, told that compression and massage are their only options, is experiencing the ceiling of what the system around them can offer. Not the ceiling of what medicine can do.
That distinction is the core of what I’ve written about in “Informed Choice Is the Intervention” and “What to Ask Before Saying Yes to Breast Reconstruction.” Shared decision-making isn’t a philosophy. It’s infrastructure. For it to work, patients need access to complete information about what the full range of options actually includes, not just what’s available at the nearest practice or easiest to explain in a fifteen-minute appointment. The fact that microsurgical lymphedema treatment exists and is effective is not obscure clinical knowledge. It’s the kind of information that belongs in front of every patient before they accept a compression garment as a permanent feature of their life.
I’ve spent years watching patients arrive at PRMA after long-term compression-only management, some of them a decade out from treatment, having never once had surgery raised as a possibility by their care team. The referrals come from across the country because the expertise exists in few places, and because no one built the system to tell patients where to look. That’s what we’re building now.
The options exist. The work is making sure patients can reach them.
Surviving cancer is not the same as recovering from it. That distinction matters to every patient organizing their daily life around a sleeve and a drainage routine.
If you or someone you know is living with lymphedema after breast cancer treatment and has been told compression is the only option, it may not be. A consultation is the right place to start. Learn more about lymphedema surgery here.
Related reading: The Wall I Kept Hitting: Why Every Venture Started the Same Way →